Approved Treatments for Angioedema

Berinert (human C1 esterase inhibitor) is an approved on-demand treatment for acute swelling attacks in children and adults with hereditary angioedema (HAE). It is given via an intravenous injection and can be self-administered. It works by replenishing C1-INH levels.

Cinryze (human C1 esterase inhibitor) is an approved routine preventive treatment for swelling attacks in children and adults with hereditary angioedema (HAE). It is administered via an intravenous injection. The therapy works by restoring C1-INH levels.

Danazol is an approved oral medication that’s used to prevent swelling attacks of all types, including those involving the skin, abdomen, and larynx, or voice box, in people with hereditary angioedema (HAE). Only generic versions of the therapy are currently available in the U.S.

Firazyr (icatibant) is an approved on-demand therapy for the management of swelling attacks in people with hereditary angioedema (HAE). It is given via a subcutaneous injection and can be self-administered. Several generic versions of the therapy are also available. in the U.S.

Haegarda (human C1 esterase inhibitor) is a prophylactic treatment approved to prevent acute swelling attacks in children and adults with hereditary angioedema (HAE). It is given via a subcutaneous injection and can be self-administered. It works by restoring C1-INH levels.

Kalbitor (ecallantide) is a medication that’s approved in the U.S. to treat swelling attacks of hereditary angioedema (HAE) in people ages 12 and older. It is given by a subcutaneous injection and works by inhibiting an enzyme that is overactive in HAE, preventing bradykinin levels from rising too high and triggering a swelling attack.

Orladeyo (berotralstat) is an approved oral therapy used for the routine prevention of swelling attacks in adults and adolescents with hereditary angioedema (HAE). It works by blocking the activity of an enzyme that is required for the production of bradykinin, the signaling molecule that is thought to act as a driver for HAE swelling attacks.

Ruconest (recombinant C1 esterase inhibitor) is an approved therapy indicated for the on-demand treatment of swelling attacks in adults and adolescents with hereditary angioedema (HAE). It is administered via an intravenous injection and works by providing patients with a lab-made version of the C1-INH protein they are missing.

Takhzyro (lanadelumab) is an injectable therapy that’s approved for preventing swelling attacks in children and adults with hereditary angioedema (HAE). It is given via a subcutaneous injection and can be self-administered. It works by inhibiting the enzyme that is required for the production of bradykinin.